Gerry Brunk Email & Phone Number
@mdscapital.com
LinkedIn matched
Who is Gerry Brunk? Overview
A concise factual answer block for searchers comparing this professional profile.
Gerry Brunk is listed as Managing Director at Lumira Ventures, based in Greater Boston, United States, United States. AeroLeads shows a work email signal at mdscapital.com and a matched LinkedIn profile for Gerry Brunk.
Gerry Brunk previously worked as Board of Directors at Spectrawave, Inc. and Board of Directors at Endogenex. Gerry Brunk holds Mba from Stanford University Graduate School Of Business.
Email format at Lumira Ventures
This section adds company-level context without repeating Gerry Brunk's masked contact details.
AeroLeads found 1 current-domain work email signal for Gerry Brunk. Compare company email patterns before reaching out.
About Gerry Brunk
Gerry Brunk is a Managing Director at Lumira Ventures. They possess expertise in biotechnology, mergers and acquisitions, venture capital, lifesciences, start ups and 18 more skills.
Listed skills include Biotechnology, Mergers And Acquisitions, Venture Capital, Lifesciences, and 19 others.
Gerry Brunk's current company
Company context helps verify the profile and gives searchers a useful next step.
Gerry Brunk work experience
A career timeline built from the work history available for this profile.
Managing Director
CurrentLumira Ventures provides capital and operating expertise to life sciences companies developing innovative products that solve significant unmet needs of patients and healthcare providers. The firm has partners in Toronto, Montreal, Vancouver and Boston.
Board Of Directors
CurrentSpectraWAVE is a privately held medical device company founded to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). SpectraWAVE’s flagship HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized.
Board Of Directors
CurrentEndogenex, a clinical stage company founded in partnership with Mayo Clinic, is focused on shifting the treatment paradigm for people living with Type 2 Diabetes. Current diabetes care focuses on the downstream consequences of this metabolic disease by targeting insulin resistance with medications and insulin replacement therapy. Endogenex’s goal is to.
Board Of Directors
CurrentHistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in.
Board Of Directores
CurrentCadence is developing a novel neuromodulation therapy for treating pediatric and adult patients with focal drug resistant epilepsy, originally developed at Mayo Clinic. The therapy utilizes chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures.
Board Of Directors
CurrentenGene Inc. is a clinical-stage biotechnology company developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical models.
Board Of Directors
CurrentPIC Therapeutics is a biotechnology company developing a new generation of cancer therapeutics based on the modulation of RNA translation.
Board Of Directors
CurrentGenEp, Inc. is a privately held pre-clinical stage biotechnology company, spun out of the University of Virginia, creating therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment resistant epilepsies.
Board Of Directors
CurrentCyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company developing a novel therapy to restore smell and flavor function. The chronic loss of smell and flavor is a condition affecting at least 5% of the U.S. population with a similar incidence in Europe and Asia. The condition is now recognized as a widely prevalent.
Board Of Directors
CurrentFor over 60 seasons, Weston Drama Workshop has provided a summer theater residency program for performers in 5th grade through age 23. Over the season WDW inspires over 200 participants to offer over 20 fully staged productions over a 10-day period at the end of July.
Board Of Directors
CurrentCorvia Medical (formerly DC Devices) is developing the first trans-catheter device for diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF)
Uva Seed Fund Advisory Committee
Current
Board Of Directors
CurrentSEMDA and SEBIO have come together as a unified voice for the Southeast’s life-science industry. We connect biopharma, medical device, diagnostics, and digital heath industries with investors, potential partners, and the resources they need to progress.
Board Of Directors
Endotronix is a digital health medtech company developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The company’s comprehensive solution includes a cloud-based disease management data system and outpatient hemodynamic management with a breakthrough implantable.
Board Observer
Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac monitors to the industry. The company’s CAM Patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that provides optimal detection and.
Board Of Directors
Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company’s lead investigational drug is Staccato® alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures
Board Of Directors
Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach.
Board Of Directors
Prior to its acquisition by Stryker Corp., MAKO Surgical Corp. (Nasdaq: MAKO) was a medical device company pioneering the field of surgical robotics with a focus on knee and hip procedures.
Board Of Directors
Prior to its acquisition by Gilead Sciences, Pharmasset was a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, with a primary focus on oral therapeutics for the treatment of Hepatitis C.
Chief Operating Officer
Founding team member of this venture-backed provider of pharmaceutical licensing and business development enterprise solutions to improve drug development collaborations among pharmaceutical firms, biotechnology companies and academic medical research institutions. Acquired in 2002 by Wolters Kluwer N.V.
Principal
Financial Analyst
Gerry Brunk education
Mba
Ba, Biology, Economics
Frequently asked questions about Gerry Brunk
Quick answers generated from the profile data available on this page.
What company does Gerry Brunk work for?
Gerry Brunk works for Lumira Ventures.
What is Gerry Brunk's role at Lumira Ventures?
Gerry Brunk is listed as Managing Director at Lumira Ventures.
What is Gerry Brunk's email address?
AeroLeads has found 1 work email signal at @mdscapital.com for Gerry Brunk at Lumira Ventures.
Where is Gerry Brunk based?
Gerry Brunk is based in Greater Boston, United States, United States while working with Lumira Ventures.
What companies has Gerry Brunk worked for?
Gerry Brunk has worked for Lumira Ventures, Spectrawave, Inc., Endogenex, Histosonics, Inc., and Cadence Neuroscience Inc..
How can I contact Gerry Brunk?
You can use AeroLeads to view verified contact signals for Gerry Brunk at Lumira Ventures, including work email, phone, and LinkedIn data when available.
What schools did Gerry Brunk attend?
Gerry Brunk holds Mba from Stanford University Graduate School Of Business.
What skills is Gerry Brunk known for?
Gerry Brunk is listed with skills including Biotechnology, Mergers And Acquisitions, Venture Capital, Lifesciences, Start Ups, Medical Devices, Strategy, and Business Development.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial